Self-reported gastrointestinal symptoms are more common in liver transplanted transthyretin amyloidosis patients than in healthy controls and in patients transplanted for end-stage liver disease Background Gastrointestinal (GI) complications are common in hereditary transthyretin (TTR) amyloid (ATTRm) amyloidosis, and previous studies indicate that the symptoms tend to increase after liver transplantation [1] . The aim of the present study was to evaluate the frequency and severity of GI symptoms in liver transplanted ATTRm amyloidosis patients compared to that of healthy controls and patients transplanted for end-stage liver disease.
Material and methods
The Gastrointestinal Symptoms Rating Scale (GSRS) is a validated self-assessment questionnaire for evaluating GI symptoms using a seven-point Likert scale [2] . We used 18 items of the GSRS grouped into seven symptom clusters, and the maximum possible score was 108. This form, together with a questionnaire on concomitant medications and diseases, was sent to 92 Swedish patients who had been transplanted for ATTRm amyloidosis between 1990 and 2012. GSRS forms were also sent to all other liver transplanted patients (n ¼ 93 as of August 2017) from the three northernmost counties in Sweden. Healthy controls were randomly selected from the Swedish Betula study, a prospective study on memory, health and aging in a normal population [3] . Polypharmacy was defined as 5 concomitant medications. Non-parametric statistical analyses were used since a normal distribution could not be guaranteed, and p < .05 was regarded as statistically significant.
Results
Seventy-seven amyloidosis patients, 53 liver transplanted controls and 154 healthy controls were included. The groups were matched for age and sex. All ATTRm patients except two carried the TTR V30M mutation, and 57% were male. Median age at liver transplantation and GSRS response was 49 (full range 25-69) years and 59 (35-75) years, respectively. The prevalence of GI symptoms was higher in ATTRm patients than in healthy controls but equal to that of transplanted controls and, among patients, abdominal pain, bloating and diarrhoea were the most common symptoms, whereas constipation and satiety were the symptoms with the highest proportion of patients reporting severe or very severe discomfort (Table 1 ). Total GSRS scores were higher in patients than in both transplanted and healthy controls (median score 26 versus 14 versus 7, p < .01). Patients also displayed higher scores than controls for most symptom clusters; however, no difference was found for either gastroesophageal reflux compared to both transplanted and healthy controls (0 versus 0 versus 0, p ¼ .56) or for diarrhoea or bloating compared to the transplanted controls (6 versus 6, p ¼ .60 and 5 versus 3, p ¼ .10, respectively). Polypharmacy was more common in ATTRm patients than in healthy controls (58% versus 11%, p < .01), but no corresponding data were available for the liver transplanted controls. Binary logistic regression analysis showed no significant association between the total GSRS score, age, sex or age at disease onset in ATTRm patients; however, polypharmacy was found to be associated with higher GSRS scores (OR 4.04, 95% CI 1.29-12.67).
Discussion/conclusions
Liver transplanted patients with ATTRm amyloidosis displayed a higher frequency and severity of GI symptoms than healthy controls and patients transplanted for endstage liver disease, and this was most evident for abdominal pain and constipation. These findings may be related to more pronounced pre-transplant GI symptoms, but also to a post-transplant disease progression. Diarrhoea and bloating, however, primarily appear to be related to post-transplant complications and medications, and not to amyloid disease progression. Further, gastroesophageal reflux does not seem to be a major problem for these patients. 
